CLDN18 and biliary tract cancer: This narrative review uniquely synthesizes the expanding landscape of CLDN18.2-directed therapies across gastric, pancreatic, and biliary tract cancers, moving beyond zolbetuximab to highlight diverse next-generation modalities, combination immunotherapy approaches, and emerging engineering platforms.